Abivax S.A.
AAVXF
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.82B
Close$
Share Statistics
| Market cap | $6.82 Billion |
|---|---|
| Enterprise Value | $6.43 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -133.12% |
|---|---|
| Return on Assets | -105.49% |
| Return on Invested Capital | -104.99% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3212.1 |
| Enterprise Value to EBIT | -15.69 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 21, 2026
EPS Estimate
$-0.92
Average shareholder expectationRevenue Estimate
$796,823
Average shareholder expectationNext Earnings Call
Expected Date
December 14, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$892,477
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Abivax
69 employees
CEO: Marc de Garidel Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectio...